These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 11979155)

  • 1. Effect of resovist on rats with different severities of liver cirrhosis.
    Kato N; Ihara S; Tsujimoto T; Miyazawa T
    Invest Radiol; 2002 May; 37(5):292-8. PubMed ID: 11979155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-dependency and rate of decay of efficacy of Resovist on MR images in a rat cirrhotic liver model.
    Kato N; Takahashi M; Tsuji T; Ihara S; Brautigam M; Miyazawa T
    Invest Radiol; 1999 Sep; 34(9):551-7. PubMed ID: 10485069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in predominant enhancement mechanisms of superparamagnetic iron oxide and ultrasmall superparamagnetic iron oxide for contrast-enhanced portal magnetic resonance angiography. Preliminary results of an animal study original investigation.
    Knollmann FD; Böck JC; Rautenberg K; Beier J; Ebert W; Felix R
    Invest Radiol; 1998 Sep; 33(9):637-43. PubMed ID: 9766048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical results with Resovist: a phase 2 clinical trial.
    Reimer P; Rummeny EJ; Daldrup HE; Balzer T; Tombach B; Berns T; Peters PE
    Radiology; 1995 May; 195(2):489-96. PubMed ID: 7724772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Magnetic resonance imaging of focal liver lesions. Comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patient.
    Vogl TJ; Hammerstingl R; Schwarz W; Kümmel S; Müller PK; Balzer T; Lauten MJ; Balzer JO; Mack MG; Schimpfky C; Schrem H; Bechstein WO; Neuhaus P; Felix R
    Invest Radiol; 1996 Nov; 31(11):696-708. PubMed ID: 8915751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging of macrophages in soft-tissue infection in rats: relationship between ultrasmall superparamagnetic iron oxide dose and MR signal characteristics.
    Lutz AM; Weishaupt D; Persohn E; Goepfert K; Froehlich J; Sasse B; Gottschalk J; Marincek B; Kaim AH
    Radiology; 2005 Mar; 234(3):765-75. PubMed ID: 15665219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MR imaging of the liver with Resovist: safety, efficacy, and pharmacodynamic properties.
    Kopp AF; Laniado M; Dammann F; Stern W; Grönewäller E; Balzer T; Schimpfky C; Claussen CD
    Radiology; 1997 Sep; 204(3):749-56. PubMed ID: 9280254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of superparamagnetic iron oxide for MR imaging of liver injury: proton relaxation mechanisms and optimal MR imaging parameters.
    Tanimoto A; Mukai M; Kuribayashi S
    Magn Reson Med Sci; 2006 Jul; 5(2):89-98. PubMed ID: 17008765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic resonance lymphography in rats: effects of muscular activity and hyperthermia on the lymph node uptake of intravenously injected superparamagnetic iron oxide particles.
    Elste V; Wagner S; Taupitz M; Pfefferer D; Kresse M; Hamm B; Berg R; Wolf KJ; Semmler W
    Acad Radiol; 1996 Aug; 3(8):660-6. PubMed ID: 8796730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SPIO-enhanced 2D-TOF MR angiography of the portal venous system: results of an intraindividual comparison.
    Reimer P; Marx C; Rummeny EJ; Müller M; Lentschig M; Balzer T; Dietl KH; Sulkowski U; Berns T; Shamsi K; Peters PE
    J Magn Reson Imaging; 1997; 7(6):945-9. PubMed ID: 9400835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver tumors in cirrhosis: experimental study with SPIO-enhanced MR imaging.
    Clement O; Frija G; Chambon C; Schouman-Clayes E; Mosnier JF; Poupon MF; Balkau B
    Radiology; 1991 Jul; 180(1):31-6. PubMed ID: 2052718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Superparamagnetic iron oxide (SPIO) enhancement in the cirrhotic liver: a comparison of two doses of ferumoxides in patients with advanced disease.
    Arnold P; Ward J; Wilson D; Ashley Guthrie J; Robinson PJ
    Magn Reson Imaging; 2003 Sep; 21(7):695-700. PubMed ID: 14559332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of a superparamagnetic iron oxide (Resovist) for MR imaging of human cerebral blood volume.
    Reimer P; Schuierer G; Balzer T; Peters PE
    Magn Reson Med; 1995 Nov; 34(5):694-7. PubMed ID: 8544689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eovist Injection and Resovist Injection: two new liver-specific contrast agents for MRI.
    Mintorovitch J; Shamsi K
    Oncology (Williston Park); 2000 Jun; 14(6 Suppl 3):37-40. PubMed ID: 10887650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contrast-enhanced MR imaging of liver and spleen: first experience in humans with a new superparamagnetic iron oxide.
    Hamm B; Staks T; Taupitz M; Maibauer R; Speidel A; Huppertz A; Frenzel T; Lawaczeck R; Wolf KJ; Lange L
    J Magn Reson Imaging; 1994; 4(5):659-68. PubMed ID: 7981510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superparamagnetic iron oxide-mediated hepatic signal intensity change in patients with and without cirrhosis: pulse sequence effects and Kupffer cell function.
    Tanimoto A; Yuasa Y; Shinmoto H; Jinzaki M; Imai Y; Okuda S; Kuribayashi S
    Radiology; 2002 Mar; 222(3):661-6. PubMed ID: 11867782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new type of susceptibility-artefact-based magnetic resonance angiography: intra-arterial injection of superparamagnetic iron oxide particles (SPIO) A Resovist in combination with TrueFisp imaging: a feasibility study.
    Maes RM; Lewin JS; Duerk JL; Misselwitz B; Kiewiet CJ; Wacker FK
    Contrast Media Mol Imaging; 2006; 1(5):189-95. PubMed ID: 17193696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of a blood-pool contrast agent for MR-guided vascular procedures: feasibility of ultrasmall superparamagnetic iron oxide particles.
    Wacker FK; Wendt M; Ebert W; Hillenbrandt C; Wolf KJ; Lewin JS
    Acad Radiol; 2002 Nov; 9(11):1251-4. PubMed ID: 12449357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Definition of liver tumors in the presence of diffuse liver disease: comparison of findings at MR imaging with positive and negative contrast agents.
    Kuwatsuru R; Brasch RC; Mühler A; Mathur A; Vexler VS; Rosenau W; Mintorovitch J; Berthezene Y; Cohen F; Shames DM
    Radiology; 1997 Jan; 202(1):131-8. PubMed ID: 8988202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo MR imaging of intravascularly injected magnetically labeled mesenchymal stem cells in rat kidney and liver.
    Bos C; Delmas Y; Desmoulière A; Solanilla A; Hauger O; Grosset C; Dubus I; Ivanovic Z; Rosenbaum J; Charbord P; Combe C; Bulte JW; Moonen CT; Ripoche J; Grenier N
    Radiology; 2004 Dec; 233(3):781-9. PubMed ID: 15486216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.